Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.39 |
| ▸ | UTRN | P46939 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25865249 | 0.80 | NPC1 (0.36) | NPC1RAB9ATP53UTRNMAPT | |
| SCHEMBL25865096 | 0.77 | MAPT (0.44) | NPC1RAB9ASMN1; SMN2TP53HDAC6 | |
| SCHEMBL25865264 | 0.76 | RAB9A (0.38) | NPC1RAB9ASMN1; SMN2TP53UTRN | |
| SCHEMBL25857105 | 0.75 | APP (0.50) | APPNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL25857070 | 0.73 | APP (0.53) | APPNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL3188032 | 0.69 | APP (0.65) | APPNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL24871280 | 0.68 | TP53 (0.59) | APPNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL11835372 | 0.68 | TP53 (0.63) | APPNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL3187032 | 0.68 | APP (0.70) | APPNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL25857103 | 0.67 | MAPT (0.46) | NPC1RAB9ASMN1; SMN2TP53HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | APP 857/4885NPC1 301/4885RAB9A 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.